Eli Lilly and Company (NYSE:LLY) Shares Acquired by Harmony Asset Management LLC

Harmony Asset Management LLC increased its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 17.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,806 shares of the company's stock after buying an additional 1,033 shares during the period. Eli Lilly and Company accounts for about 2.1% of Harmony Asset Management LLC's investment portfolio, making the stock its 9th biggest holding. Harmony Asset Management LLC's holdings in Eli Lilly and Company were worth $5,254,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. Knightsbridge Asset Management LLC boosted its position in shares of Eli Lilly and Company by 1.9% during the fourth quarter. Knightsbridge Asset Management LLC now owns 813 shares of the company's stock worth $628,000 after purchasing an additional 15 shares in the last quarter. Centerpoint Advisory Group acquired a new stake in Eli Lilly and Company during the 4th quarter worth $514,000. Kentucky Trust Co acquired a new stake in Eli Lilly and Company during the 4th quarter worth $834,000. CSM Advisors LLC lifted its holdings in Eli Lilly and Company by 30.6% during the fourth quarter. CSM Advisors LLC now owns 1,045 shares of the company's stock worth $807,000 after acquiring an additional 245 shares in the last quarter. Finally, Proficio Capital Partners LLC lifted its holdings in shares of Eli Lilly and Company by 30.2% during the 4th quarter. Proficio Capital Partners LLC now owns 6,739 shares of the company's stock valued at $5,202,000 after purchasing an additional 1,562 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Performance

LLY stock traded down $1.21 during mid-day trading on Monday, hitting $713.99. 2,631,160 shares of the company were exchanged, compared to its average volume of 3,622,393. Eli Lilly and Company has a 1-year low of $677.09 and a 1-year high of $972.53. The stock has a market capitalization of $676.67 billion, a PE ratio of 60.97, a price-to-earnings-growth ratio of 1.40 and a beta of 0.48. The business has a 50 day simple moving average of $789.29 and a 200-day simple moving average of $803.22. The company has a current ratio of 1.15, a quick ratio of 0.97 and a debt-to-equity ratio of 2.00.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its earnings results on Thursday, May 1st. The company reported $3.34 earnings per share for the quarter, missing analysts' consensus estimates of $4.64 by ($1.30). The firm had revenue of $12.73 billion for the quarter, compared to the consensus estimate of $12.77 billion. Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. Eli Lilly and Company's revenue for the quarter was up 45.2% on a year-over-year basis. During the same quarter last year, the business posted $2.58 EPS. On average, equities analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Friday, May 16th will be given a $1.50 dividend. The ex-dividend date is Friday, May 16th. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.84%. Eli Lilly and Company's payout ratio is presently 48.82%.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on LLY. HSBC cut shares of Eli Lilly and Company from a "buy" rating to a "reduce" rating and reduced their price target for the company from $1,150.00 to $700.00 in a report on Monday, April 28th. Truist Financial lifted their price target on Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the company a "buy" rating in a research note on Monday, February 3rd. UBS Group reduced their price target on Eli Lilly and Company from $1,100.00 to $1,050.00 and set a "buy" rating for the company in a research report on Friday, May 2nd. The Goldman Sachs Group upgraded shares of Eli Lilly and Company from a "neutral" rating to a "buy" rating and lowered their price objective for the company from $892.00 to $888.00 in a report on Tuesday, April 8th. Finally, Wells Fargo & Company reissued an "overweight" rating on shares of Eli Lilly and Company in a research report on Thursday, May 1st. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and eighteen have given a buy rating to the company. According to MarketBeat, Eli Lilly and Company has an average rating of "Moderate Buy" and an average price target of $1,011.37.

Insider Activity at Eli Lilly and Company

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of the stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $818.24, for a total transaction of $818,240.00. Following the transaction, the chief accounting officer now owns 5,840 shares in the company, valued at $4,778,521.60. This represents a 14.62% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.13% of the stock is currently owned by corporate insiders.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.